Skip to content
10-Q

Quarterly Report

Rapport Therapeutics, Inc. RAPP

0001193125-26-210355

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 4, 2026 47.83M sh
Shares Diluted Q1 2026 · Mar 31, 2026 47.24M sh
Shares Diluted Q1 2026 · Mar 31, 2025 35.27M sh
Capex Q1 2026 · Mar 31, 2026 $86K
Capex Q1 2026 · Mar 31, 2025 $291K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$13.06M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$20.24M
Short Term Investments Q1 2026 · Mar 31, 2026 $398.73M
Short Term Investments Q1 2026 · Dec 31, 2025 $437.89M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $78.06M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $52.65M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $57.6M
Stockholders Equity Q1 2026 · Mar 31, 2026 $471.51M
Stockholders Equity Q1 2026 · Dec 31, 2025 $484.65M
Stockholders Equity Q1 2026 · Mar 31, 2025 $285.84M
Stockholders Equity Q1 2026 · Dec 31, 2024 $305.43M
Current Liabilities Q1 2026 · Mar 31, 2026 $17.9M
Current Liabilities Q1 2026 · Dec 31, 2025 $19.05M
Total Liabilities Q1 2026 · Mar 31, 2026 $26.09M
Total Liabilities Q1 2026 · Dec 31, 2025 $27.78M
Current Assets Q1 2026 · Mar 31, 2026 $484.7M
Current Assets Q1 2026 · Dec 31, 2025 $498.56M
Total Assets Q1 2026 · Mar 31, 2026 $497.6M
Total Assets Q1 2026 · Dec 31, 2025 $512.43M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.42
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.68
Eps Basic Q1 2026 · Mar 31, 2026 −$0.42
Eps Basic Q1 2026 · Mar 31, 2025 −$0.68
Sga Expense Q1 2026 · Mar 31, 2026 $11.5M
Sga Expense Q1 2026 · Mar 31, 2025 $7.54M
Rd Expense Q1 2026 · Mar 31, 2026 $32.72M
Rd Expense Q1 2026 · Mar 31, 2025 $19.57M
Net Income Q1 2026 · Mar 31, 2026 −$19.86M
Net Income Q1 2026 · Mar 31, 2025 −$24.06M
Operating Income Q1 2026 · Mar 31, 2026 −$24.22M
Operating Income Q1 2026 · Mar 31, 2025 −$27.11M
Revenue Q1 2026 · Mar 31, 2026 $20M
Revenue Q1 2026 · Mar 31, 2025 $0